Change of Adviser

RNS Number : 6359Y
Proteome Sciences PLC
05 March 2012
 



 

Proteome Sciences plc

(the "Company")

Change of Adviser and Broker

The Company announces the appointment of Cenkos Securities plc, as Nominated Adviser and Broker to the Company, with immediate effect.

 

For further information please contact:

Proteome Sciences plc

www.proteomics.com

Christopher Pearce, Chief Executive Officer

James Malthouse, Finance Director

Dr. Ian Pike, Chief Operating Officer

 

 

Tel: +44 (0)1932 865065

christopher.pearce@proteomics.com

james.malthouse@proteomics.com

ian.pike@proteomics.com

 

Nominated Adviser

Cenkos Securities plc

Stephen Keys/Camilla Hume

 

Tel: +44 (0)20 7397 8900

 

Public Relations

FTI Consulting

Ben Atwell/Mo Noonan

Tel:       +44 (0)20 7269 7116

Email:   mo.noonan@fticonsulting.com

 

 

IKON Associates

Adrian Shaw

Tel:       +44 (0)1483 271291

Mobile:  +44 (0)7979 900733

Email: Adrian@ikonassociates.com

 

Notes to Editors:

 

About Proteome Sciences

Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development.

 

Its PS Biomarker Services™ uses isobaric and isotopic Tandem Mass Tag® (TMT®) workflows developed on the latest Orbitrap Velos and TSQ Vantage mass spectrometers to deliver rapid, robust and reproducible biomarker assay development for customers in the pharmaceutical, diagnostic and biotechnology sectors. Services are provided from its ISO 9001: 2008 accredited facilities in Frankfurt, Germany. By combining Selected Reaction Monitoring (SRM) and TMT workflows highly multiplexed assays can be developed rapidly and are suitable for screening hundreds of candidate biomarkers in larger validation studies and can be transferred for immunoassay development. The Company's own research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers, including Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or are already outlicensed. Proteome Sciences, based in Cobham, UK, with facilities in London and Frankfurt, delivers outsourced proteomics services and proprietary biomarkers/biomarker assays to pharmaceutical, biotechnology and diagnostics companies.

Visit:  http://www.proteomics.com.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
APPLLFFDVIIFIIF
UK 100

Latest directors dealings